• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza in Patients with Hematological Malignancies: Experience at Two Comprehensive Cancer Centers

tetano

Editor, Senior Moderator
J Med Virol. 2017 Aug 29. doi: 10.1002/jmv.24930. [Epub ahead of print]
[h=1]Influenza in Patients with Hematological Malignancies: Experience at Two Comprehensive Cancer Centers.[/h] Vilar-Compte D[SUP]1[/SUP], Shah DP[SUP]2[/SUP], Vanichanan J[SUP]2[/SUP], Cornejo-Juarez P[SUP]1[/SUP], Garcia-Horton A[SUP]1,[/SUP][SUP]3[/SUP], Volkow P[SUP]1[/SUP], Chemaly RF[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The burden of influenza infections in patients with hematological malignancies (HMs) is not well defined.
[h=4]OBJECTIVE:[/h] To describe the associated outcomes at two comprehensive cancer centers (center 1 in the United States and center 2 in Mexico).
[h=4]PATIENTS/METHODS:[/h] Clinical and laboratory data on patients with HMs and influenza infection diagnosed from April 2009 to May 2014 at the two centers were reviewed retrospectively.
[h=4]RESULTS:[/h] In our cohort of 190 patients, the majority were male (63%) with a median age of 49 years (range, 1-88 years), and had active or refractory HMs (76%). Compared to center 1, patients in center 2 were significantly sicker (active cancer, decreased albumin levels, elevated creatinine levels, or hypoxia at influenza diagnosis) and experienced higher lower respiratory tract infection (LRI) rate (42% vs. 7%; P < 0.001). In multivariable logistic regression analysis (odds ratio, 95% confidence interval), leukemia, (3.09, 1.23-7.70), decreased albumin level (3.78, 1.55-9.20), hypoxia at diagnosis (14.98, 3.30-67.90), respiratory co-infection (5.87, 1.65-20.86), and corticosteroid use (2.71, 1.03-7.15) were significantly associated with LRI; and elevated creatinine level (3.33, 1.05-10.56), hypoxia at diagnosis (5.87, 1.12-30.77), and respiratory co-infection (6.30, 1.55-25.67) were significantly associated with 60 day mortality in both centers.
[h=4]CONCLUSIONS:[/h] HM patients with influenza are at high risk for serious complications such as LRI and death, especially if they are immunosuppressed. Patients with respiratory symptoms should seek prompt medical care during influenza season. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] H1N1; Influenza; cancer; leukemia; lymphoma; myeloma; pneumonia

PMID: 28851056 DOI: 10.1002/jmv.24930
 
Back
Top Bottom